Skip to content

Genzyme And Isis Pharmaceuticals’ Orphan Drug Kynamro (Mipomersen): RNAi Therapeutics Blog Perspective

October 29, 2012

       The RNAi Therapeutics Blog, posts an October 26, 2012 Blog Post titled,”The Mipomersen Briefing Docs: Gymnotic Delivery Revealed”, that reviews and discusses the FDA Briefing Documents. 

       Per the RNAi Therapeutics Blog Post, a few “surprises were revealed in the Briefing Docs” : 

1)  Liver Fat : More & Persistent

2)  Partial Clinical Hold: Vasculitis

3)  Liver Enzyme Increases

4)  Injection-Site Reactions & Discontinuations

5)  Increased Development Of Cancer

6)  Kidney Damage.       

Copyright  © 2012-2013, Ann-Teresa Cusenza and Orphan Druganaut Blog.  All rights reserved.

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: